Anti-Human PTGS2 (Clone CPTC-PTGS2-1) – Purified No Carrier Protein

PTGS2 Synthetic peptide ALPPVPDD(Cam)PTPLGVK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0124B-2D1-H1/K1 activity is directed against human PTGS2, peptide sequence ALPPVPDDCPTPLGVK.

CPTC-PTGS2-1

PTGS is a key enzyme involved in prostanoid synthesis that is expressed as two, functionally different isoforms, PTGS1 and PTGS2, from two separate genes¹. Prostanoids are potent bioactive lipid messengers in normal physiology and disease. PTGS provides the rate-limiting step in their synthesis. PTGS2 expression is induced in response to pro-inflammatory factors, hormones, growth factors, and oncogenes, while glucocorticoids inhibit expression. Additionally, PTGS2 influences the pathogenesis of cancer, atherosclerosis, Alzheimer’s disease, and inflammatory and immune disorders. PTGS2, via its metabolite prostaglandin E2, induces cancer stem cell activity, promotes apoptotic resistance, proliferation, angiogenesis, inflammation, invasion, and metastasis². As such, PTGS2 (also known as COX-2) selective inhibitors have been developed to treat pain and inflammation and may prove useful in the prevention of tumor metastasis².

EB0124B-2D1-H1/K1 was generated for use in immuno-MRM assays in rabbit using a synthetic peptide derived from residues 137-162 of human PTGS2 that is carbamidomethylated at the cysteine residue: ALPPVPDDC[cam]PTPLGVK³.

EB0124B-2D1-H1/K1 can be used in Western blot analysis to detect recombinant PTGS2 protein or PTGS2 in cell lysates of Jurkat, HeLa, H226, A549 (weakly), and NCI H226 cell lines⁴. EB0124B-2D1-H1/K1 does not detect PTGS2 by immunohistochemistry, immunofluorescence, or reverse phase protein array.

PTGS2 is found in the parenchymal cells of most tissues. PTGS2 is also upregulated in a variety of pathological conditions, including cancer. PTGS2 is released by cancer-associated fibroblasts, macrophage type 2 cells, and cancer cells to the tumor microenvironment. PTGS2 can be found on the luminal side of the endoplasmic reticulum and nuclear envelope.

Heme, Arachidonic acid

1 Zidar N, Odar K, Glavac D, et al. J Cell Mol Med. 13(9B):3753-3763. 2009.
2 Hashemi Goradel N, Najafi M, Salehi E, et al. J Cell Physiol. 234(5):5683-5699. 2019.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-PTGS2-1